S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
NYSE:EW

Edwards Lifesciences - EW Stock Forecast, Price & News

$99.51
-1.02 (-1.01%)
(As of 08/18/2022 05:26 PM ET)
Add
Compare
Today's Range
$98.31
$100.57
50-Day Range
$86.50
$107.29
52-Week Range
$85.58
$131.73
Volume
2.32 million shs
Average Volume
2.70 million shs
Market Capitalization
$61.69 billion
P/E Ratio
43.08
Dividend Yield
N/A
Price Target
$125.90

Edwards Lifesciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.85 Rating Score
Upside/​Downside
26.5% Upside
$125.90 Price Target
Short Interest
Healthy
0.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.95
Upright™ Environmental Score
News Sentiment
0.24mentions of Edwards Lifesciences in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$9.74 M Sold Last Quarter
Proj. Earnings Growth
8.37%
From $2.51 to $2.72 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.96 out of 5 stars

Medical Sector

37th out of 1,119 stocks

Surgical Appliances & Supplies Industry

3rd out of 23 stocks

EW stock logo

About Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $100.53 on Thursday. The business's 50-day moving average price is $98.15 and its 200 day moving average price is $104.98. The company has a quick ratio of 2.60, a current ratio of 3.37 and a debt-to-equity ratio of 0.10. The firm has a market cap of $62.32 billion, a P/E ratio of 43.52, a P/E/G ratio of 3.01 and a beta of 1.12. Edwards Lifesciences has a 52-week low of $85.58 and a 52-week high of $131.73.

Edwards Lifesciences (NYSE:EW - Get Rating) last released its earnings results on Thursday, July 28th. The medical research company reported $0.63 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.64 by ($0.01). Edwards Lifesciences had a net margin of 27.18% and a return on equity of 24.77%. The company had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same period in the previous year, the firm posted $0.64 EPS. The company's revenue for the quarter was down .2% on a year-over-year basis. On average, equities research analysts expect that Edwards Lifesciences will post 2.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Morgan Stanley decreased their target price on Edwards Lifesciences from $136.00 to $119.00 and set an "overweight" rating on the stock in a research note on Friday, July 15th. Canaccord Genuity Group cut shares of Edwards Lifesciences from a "buy" rating to a "hold" rating and reduced their price target for the stock from $115.00 to $106.00 in a research report on Friday, July 29th. Citigroup dropped their price objective on shares of Edwards Lifesciences from $134.00 to $115.00 and set a "buy" rating for the company in a report on Tuesday, May 17th. Cowen cut their price objective on Edwards Lifesciences from $140.00 to $125.00 in a research report on Monday, July 11th. Finally, William Blair reissued an "outperform" rating on shares of Edwards Lifesciences in a research note on Tuesday, April 26th. Three investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $126.19.

Insider Activity

In other Edwards Lifesciences news, VP Bernard J. Zovighian sold 4,809 shares of the business's stock in a transaction that occurred on Tuesday, May 24th. The stock was sold at an average price of $95.52, for a total transaction of $459,355.68. Following the transaction, the vice president now owns 39,816 shares in the company, valued at approximately $3,803,224.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Edwards Lifesciences news, VP Daveen Chopra sold 1,000 shares of the company's stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $98.31, for a total transaction of $98,310.00. Following the transaction, the vice president now directly owns 19,911 shares in the company, valued at $1,957,450.41. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Bernard J. Zovighian sold 4,809 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, May 24th. The shares were sold at an average price of $95.52, for a total transaction of $459,355.68. Following the sale, the vice president now owns 39,816 shares of the company's stock, valued at $3,803,224.32. The disclosure for this sale can be found here. Insiders have sold a total of 100,937 shares of company stock valued at $9,738,239 over the last quarter. Corporate insiders own 1.29% of the company's stock.

Receive EW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

EW Stock News Headlines

Edwards Lifesciences (NYSE: EW)
Edwards Lifesciences (NYSE:EW) Raised to "Buy" at StockNews.com
Edwards Lifesciences Corp. Q2 Profit Decreases, misses estimates
See More Headlines
Receive EW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

EW Company Calendar

Last Earnings
7/28/2022
Today
8/18/2022
Next Earnings (Estimated)
10/26/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
28176E10
Employees
15,700
Year Founded
1958

Price Target and Rating

Average Stock Price Forecast
$125.90
High Stock Price Forecast
$144.00
Low Stock Price Forecast
$106.00
Forecasted Upside/Downside
+26.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.85
Research Coverage
20 Analysts

Profitability

Net Income
$1.50 billion
Pretax Margin
31.15%

Debt

Sales & Book Value

Annual Sales
$5.23 billion
Cash Flow
$2.40 per share
Book Value
$9.59 per share

Miscellaneous

Free Float
611,946,000
Market Cap
$61.69 billion
Optionable
Optionable
Beta
1.12

Social Links


Key Executives

  • Mr. Michael A. MussallemMr. Michael A. Mussallem (Age 69)
    Chairman & CEO
    Comp: $2.88M
  • Mr. Scott B. UllemMr. Scott B. Ullem (Age 55)
    Corp. VP & CFO
    Comp: $1.32M
  • Mr. Donald E. Bobo Jr.Mr. Donald E. Bobo Jr. (Age 60)
    Corp. VP of Strategy & Corp. Devel.
    Comp: $1.26M
  • Mr. Larry L. WoodMr. Larry L. Wood (Age 56)
    Corp. VP of Transcatheter Aortic Valve Replacement
    Comp: $1.31M
  • Mr. Jean-Luc  LemercierMr. Jean-Luc Lemercier (Age 65)
    Corp. VP of Europe, Middle East, Africa, Canada & Latin America
    Comp: $1.43M
  • Dr. Todd J. Brinton
    Corp. VP of Advanced Technology & Chief Scientific Officer
  • Mark Wilterding
    VP of Investor Relations
  • Mr. Arnold A. Pinkston (Age 63)
    Corp. VP & Gen. Counsel
  • Mr. Dirksen J. Lehman
    Corp. VP of Public Affairs
  • Ms. Christine Z. McCauley (Age 57)
    Corp. VP of HR













EW Stock - Frequently Asked Questions

Should I buy or sell Edwards Lifesciences stock right now?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last twelve months. There are currently 3 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EW shares.
View EW analyst ratings
or view top-rated stocks.

What is Edwards Lifesciences' stock price forecast for 2022?

20 Wall Street research analysts have issued twelve-month price objectives for Edwards Lifesciences' stock. Their EW share price forecasts range from $106.00 to $144.00. On average, they expect the company's stock price to reach $125.90 in the next twelve months. This suggests a possible upside of 25.2% from the stock's current price.
View analysts price targets for EW
or view top-rated stocks among Wall Street analysts.

How have EW shares performed in 2022?

Edwards Lifesciences' stock was trading at $129.55 at the beginning of 2022. Since then, EW stock has decreased by 22.4% and is now trading at $100.53.
View the best growth stocks for 2022 here
.

Are investors shorting Edwards Lifesciences?

Edwards Lifesciences saw a drop in short interest in the month of July. As of July 31st, there was short interest totaling 5,540,000 shares, a drop of 16.8% from the July 15th total of 6,660,000 shares. Based on an average daily volume of 2,680,000 shares, the days-to-cover ratio is presently 2.1 days. Currently, 0.9% of the company's shares are sold short.
View Edwards Lifesciences' Short Interest
.

When is Edwards Lifesciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our EW earnings forecast
.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Co. (NYSE:EW) posted its quarterly earnings results on Thursday, July, 28th. The medical research company reported $0.63 earnings per share for the quarter, missing the consensus estimate of $0.64 by $0.01. The medical research company had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a net margin of 27.18% and a trailing twelve-month return on equity of 24.77%. The company's revenue for the quarter was down .2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.64 EPS.
Read the conference call transcript
.

When did Edwards Lifesciences' stock split?

Edwards Lifesciences's stock split on the morning of Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly created shares were issued to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences updated its FY 2022 earnings guidance on Thursday, August, 4th. The company provided EPS guidance of $2.50-$2.50 for the period, compared to the consensus EPS estimate of $2.56. The company issued revenue guidance of $5.35 billion-$5.55 billion, compared to the consensus revenue estimate of $5.71 billion.

What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO?

389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees.

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bank of Nova Scotia (93.89%), State Street Corp (4.34%), Brown Advisory Inc. (2.57%), Sands Capital Management LLC (1.89%), FMR LLC (1.43%) and Northern Trust Corp (1.06%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers, Scott B Ullem and William J Phd Link.
View institutional ownership trends
.

How do I buy shares of Edwards Lifesciences?

Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Edwards Lifesciences' stock price today?

One share of EW stock can currently be purchased for approximately $100.53.

How much money does Edwards Lifesciences make?

Edwards Lifesciences (NYSE:EW) has a market capitalization of $62.32 billion and generates $5.23 billion in revenue each year. The medical research company earns $1.50 billion in net income (profit) each year or $2.31 on an earnings per share basis.

How many employees does Edwards Lifesciences have?

The company employs 15,700 workers across the globe.

Does Edwards Lifesciences have any subsidiaries?
The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.
Read More
When was Edwards Lifesciences founded?

Edwards Lifesciences was founded in 1958.

How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The official website for the company is www.edwards.com. The medical research company can be reached via phone at (949) 250-2500, via email at investor_relations@edwards.com, or via fax at 949-250-2525.

This page (NYSE:EW) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.